A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin.
Thirty-two patients with sight-threatening uveitis and a decrease in visual acuity requiring systemic therapy were randomly assigned to either cyclosporine A or G in a dose-escalation study. Groups received from 2.5 mg/kg of body weight/day to 10 mg/kg of body weight/day of either drug along with low-dose prednisone. More patients taking cyclosporine G had improved visual acuity and a decrease in macular edema, which occurred more rapidly than in the other group, even at the lower doses tested. No difference in renal function was noted between groups at any doses tested. Four patients receiving cyclosporine G had hepatic alterations, but only one required cessation of the drug. The study indicates the potential usefulness of cyclosporine G, particularly at lower doses (4 mg/kg of body weight/day), which could lower the potential for serious renal complications.
Nussenblatt
R B
RB
Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892.
de Smet
M D
MD
Rubin
B
B
Freidlin
V
V
Whitcup
S M
SM
Davis
J
J
Herman
D
D
Bloom
J N
JN
Sran
P K
PK
Whitcher
S
S
D000328:Adult; D016572:Cyclosporine / Q000008:administration & dosage* / Q000009:adverse effects; D003524:Cyclosporins / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D011241:Prednisone / Q000008:administration & dosage; D014605:Uveitis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D014786:Vision Disorders / Q000209:etiology* / Q000517:prevention & control; D014792:Visual Acuity / Q000187:drug effects
D003524:Cyclosporins; D007166:Immunosuppressive Agents; C045571:cyclosporin G; D016572:Cyclosporine; D011241:Prednisone